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Summary
Primary Hypercalciuria (PH) is very often accompanied with
some degrees of bone demineralization. The most frequent
clinical condition in which this association has been observed
is calcium nephrolithiasis. In patients affected by this disorder
bone density is very frequently low and increased susceptibil-
ity to fragility fractures is reported. The very poor definition of
this bone disease from a histomorphometric point of view is a
crucial aspect. At present, the most common finding seems to
be a low bone turnover condition. Many factors are involved in
the complex relationships between bone loss and PH. Since
bone loss was mainly reported in patients with fasting hyper-
calciuria, a primary alteration in bone metabolism was pro-
posed as a cause of both hypercalciuria and bone demineral-
ization. This hypothesis was strengthened by the observation
that some bone resorbing-cytokines, such as IL-1, IL-6, and
TNF-α are high in hypercalciuric patients. The effect of an ex-
cessive response to the acid load induced by dietary protein
intake seems an additional factor explaining a primitive alter-
ation of bone. The intestine plays a major role in the clinical
course of bone disease in PH. Patients with absorptive hyper-
calciuria less frequently show bone disease and a reduction in
dietary calcium greatly increases the probability of bone loss
in PH subjects. It has recently been reported that greater bone
loss is associated with a larger increase in intestinal calcium
absorption in PH patients. Considering the absence of PTH al-
terations, it was proposed that this is not a compensatory
phenomenon, but probably the marker of disturbed cell calci-
um transport, involving both intestinal and bone tissues.
While renal hypercalciuria is rather uncommon, the kidney
still seems to play a role in the pathogenesis of bone loss of
PH patients, possibly via the effect of mild to moderate urinary
phosphate loss with secondary hypophosphatemia. In conclu-
sion, bone loss is very common in PH patients. Even if most
of the factors involved in this process have been identified,
many aspects of this intriguing clinical condition remain to be
elucidated.
KEY WORDS: bone density, intestinal calcium absorption, osteoporosis,
phosphate metabolism, primary hypercalciuria.
Introduction
Hypercalciuria is a common metabolic defect that can frequent-
ly be detected by clinicians in several conditions. This alter-
ation was firstly described by Flocks and colleagues in 1939.
However, it was Albright who first introduced the term “Idio-
pathic (or Primary) Hypercalciuria” to define a form of elevated
urinary calcium excretion that can be observed in spite of the
absence of any clinical conditions or treatments capable of in-
ducing this defect (1). Nowadays, hypercalciuria is a well-rec-
ognized condition, which especially affects patients with kidney
stones with an incidence of 50-60% in these subjects (2-4).
The use of appropriate reference ranges for normal urine calci-
um excretion is mandatory in order to make a correct diagnosis
of hypercalciuria. However, the definition of the upper normal
limit for urine calcium excretion is still a matter of debate. Many
years ago, Pak et al. (5) defined hypercalciuria as a condition
characterized by 24-hour urine calcium excretion greater than
250 mg/day in females and 300 mg/day in males, while pa-
tients are on their usual diet. In the attempt to adjust urine cal-
cium excretion for body weight, they also defined hypercalci-
uria as a 24-hour urine excretion greater than 4 mg/kg of body
weight/day in both sexes (5). This definition was criticized be-
cause it was based on a study on an adult population of a par-
ticular geographic area that did not provide any corrections for
the dietetic calcium intake of the subjects studied. This could
limit the appropriateness of this definition, especially in the
case of particular classes of persons, such as infants or elderly
people. However, very few attempts have been made to solve
the issue. Heaney et al. (6) tried to redefine the normal limits
for urine calcium excretion by adjusting for menopausal status
and dietary calcium intake. They found that in normal post-
menopausal women at moderate or high calcium intake 24-
hour urine calcium excretion exceeded the normal value of 250
mg/day and they postulated that for this subset of subjects the
upper normal limit of calcium excretion should be considered at
least 286 mg of calcium per day. However, it is well-known that
even in healthy adults dietary calcium intake rarely approaches
moderate or high values, being very frequently moderate or
frankly below the normal requirements, at least in Western
countries (7). In these subjects, the upper limits for 24-hour
urine calcium excretion found by Heaney et al. (6) were very
close to those reported by Pak et al. (5). Consequently, on the
ground of the currently available evidence and in view of future
more reliable data, it is reasonable to use Pak et al’s definition,
which was formulated on the basis of a larger cohort of patients
than that of Heaney and colleagues, at least for adult people.
In contrast, because of the marked differences in calcium me-
tabolism and dietary habits, it is still rather questionable
whether these limits should be adopted tout court for infants
and adolescents. 
To make a proper diagnosis of hypercalciuria a 24-hour urine
collection without dietetic manipulations must be obtained.
Considering the importance of the pre-analytical variability,
which is mainly related to possible errors in urine collection and
conservation, the assessment of urine calcium excretion on
two consecutive 24-hour samples is generally recommended to
confirm the presence of hypercalciuria. However, problems in
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both urine collection and storage tend to induce under- rather
than overestimation of calcium excretion. Thus, in the absence
of a true analytical error, it is rather unlikely that high urine cal-
cium excretion may represent a false positive result. 
Apart from pathological conditions (Tab. I), several factors in-
fluence urinary calcium excretion in humans. Among these, the
most important are sex, body weight, and intake of a number of
nutrients, such as sodium, potassium, phosphate, proteins,
carbohydrates, as well as alcohol. The amount of dietary calci-
um and the efficiency of intestinal calcium absorption are par-
ticularly important. Healthy subjects are estimated to eliminate
about 6-7% of dietary calcium in urine daily. Consequently, de-
pending on the different ages, an excess of dietary calcium
(greater than 1500 mg/day) can be associated with the devel-
opment of hypercalciuria.
Dietary sodium intake may affect calcium excretion by increas-
ing it of about 20-40 mg/day for every increment of 2.3 g of
sodium (8). Phosphate metabolism largely influences urine cal-
cium excretion. Phosphate leak and consequent hypophos-
phatemia stimulate renal production of 1,25-(OH)2 vitamin D,
which in turn increases intestinal calcium absorption, then pos-
sibly leading to hypercalciuria. Several epidemiological studies
confirmed the association between dietary protein intake and
calcium metabolism and its excretion. Some investigators con-
cluded that dietary proteins are more important as regulators of
urinary calcium than dietary calcium intake (9-11). Moderately
protein diets (in the range of 1.0-1.5 g proteins/kg) are associ-
ated with normal calcium metabolism and presumably do not
alter skeletal homeostasis. Subjects with high protein intake,
particularly from omnivorous sources, develop sustained hy-
percalciuria. This seems to be due to an increase in bone re-
sorption, secondary to the excessive acid load, as well as to
the direct effects of proteins on calcium handling at the renal
tubular and intestinal level (11).
Hypercalciuria is commonly distinguished in a secondary form
when it is associated with conditions that can induce its pres-
ence (Tab. I), or primary, in the absence of a specific cause.
Primary Hypercalciuria (PH)
Definition
Primary (or Idiopathic) Hypercalciuria is defined as the form of ex-
cessive calcium excretion that is not associated with conditions
known to increase calcium elimination. This definition, which was
first used by Albright (1), was almost completely maintained by
Pak et al. (5). However, according to the more recent view that di-
etetic factors can widely influence urine calcium excretion, “true”
primary hypercalciuria is considered the form of urinary calcium
excess that does not depend on known conditions and in which
possible dietetic disturbances have been eliminated by keeping
patients on a daily diet with 1000-1200 mg of calcium and no
more than 1-1.5 g/kg body weight (BW) of proteins (11). This defi-
nition can be considered restrictive as compared to that by Al-
bright and Pak. According to the new definition, some patients
are no longer classified as hypercalciuric as before. However, it is
well-known that a diet exceeding the above-mentioned range for
daily calcium and protein intake affects calcium excretion even in
patients with no evidence of intrinsic alterations of calcium metab-
olism, who would be misclassified as hypercalciuric. 
Already in the Eighties, Pak et al. (12) classified PH by dividing it
into three distinct pathogenetic pathways, according to three in-
dependent primary metabolic defects: 1) absorptive hypercalci-
uria type I, when primary intestinal hyperabsorption of calcium is
involved; 2) absorptive hypercalciuria type III, when a primary re-
nal leak of phosphate is present, thus inducing hypophos-
phatemia and secondarily 1,25-(OH)2 vitamin D-mediated intesti-
nal hyperabsorption of calcium; 3) renal hypercalciuria, when a
primary renal leak of calcium with secondary compensatory hy-
perparathyroidism is present. Pak et al. also distinguished a form
of so-called “reabsorptive hypercalciuria”, when hypercalciuria is
induced by an excessive output of calcium from bone, for exam-
ple in patients with Primary Hyperparathyroidism.
However, this classification has widely been revised over the
last twenty years on the basis of new pathophysiological obser-
vations and of a more thorough clinical and laboratory exami-
nation of patients affected by this condition. Nowadays, it is be-
lieved that, beyond the need for a classifying approach, three
different pathophysiological mechanisms, possibly overlapping
and operating together in a complex network, are involved in
the pathogenesis of hypercalciuria: increased intestinal absorp-
tion of calcium, primary excessive calcium release from bone,
and altered renal calcium handling.
Pathophysiology
1. Increased intestinal absorption of calcium 
Recent studies definitely confirmed that calcium absorption is
almost invariably increased in patients with PH (13). Broadus
Table I - Causes of secondary hypercalciuria
Diet-dependent
Excessive dietary intake of 
• Calcium
• Sodium
• Animal proteins
• Carbohydrates
• Alcohol 
Reduced intake/absorption of
• Phosphate
• Potassium
Secondary increase in intestinal calcium absorption 
Vitamin D therapy 
Endogenous over production of 1,25-(OH)2 vitamin D 
• Primary hyperparathyroidism
• Granulomatous diseases 
• Lymphomas
• Severe hypophosphatemic diseases
Increased osteoclastic resorption of bone 
Bone metastases
Multiple myeloma
Primary hyperparathyroidism
Paget’s disease of bone
Hyperthyroidism
Prolonged immobility
Reduced renal tubular reabsorption of calcium 
Loop diuretics
Bartter syndrome
Medullary sponge kidney disease
Primary renal tubular defects
Endogenous/exogenous glucocorticoid excess
Genetic alterations (chloride channels, calcium-sensing receptor)
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and colleagues found that 1,25-(OH)2 vitamin D metabolism can
be altered in patients with absorptive hypercalciuria, then being
responsible for the intestinal calcium hyperabsorption seen in
these patients (14). Since these observations have not been
confirmed by others, it has been proposed that intestinal calci-
um absorption may be increased irrespective of the elevation in
1,25-(OH)2 vitamin D. Indeed, in rats with genetic-determined
hypercalciuria an increased expression of the vitamin D recep-
tor at the intestinal level was reported (15), thus explaining the
reason why intestinal calcium absorption can be increased even
in the absence of elevated values of serum 1,25-(OH)2 vitamin
D. However, there is no evidence that a similar mechanism may
be operating in humans (16). When present, altered renal han-
dling of phosphate with excessive phosphaturia, which will then
induce hypophosphatemia, may be responsible for overproduc-
tion of 1,25-(OH)2 vitamin D with secondary intestinal calcium
hyperabsorption (17).
2. Renal tubular calcium leak
A defect in renal tubular calcium reabsorption was demonstrat-
ed in both humans and genetic hypercalciuric stone forming
rats as a cause of idiopathic hypercalciuria (18, 19). However,
an extensive revision of the cases of so-called “renal hypercal-
ciuria” demonstrated that, in contrast with previous reports, the
two distinctive characteristics of this form – that is, low-normal
serum calcium and increased PTH levels – were present in a
small minority of patients with PH (20). It is currently believed
that no more than 2-3% of PH cases are generated by a true
calcium leak.
3. Fasting Hypercalciuria 
Most patients with PH show persistence of elevated urine calci-
um even after a low calcium diet or in fasting conditions, which
is not associated with any secondary parathyroid hyperfunc-
tion. This metabolic pattern tends to exclude a major role for
both intestinal calcium hyperabsorption and renal calcium leak.
The term Fasting Hypercalciuria was formulated for this condi-
tion and it was assumed that primary excess of calcium output
from bone explained this defect (21). 
Diagnosis of PH
Once the diagnosis of hypercalciuria is correctly made, it is
necessary to exclude any secondary causes of hypercalciuria
(Tab. I). In the presence of Primary Hypercalciuria, it is gener-
ally advisable to perform some simple additional laboratory
tests to identify the main metabolic defect (Fig. 1). Briefly, after
a week of low calcium, normal sodium, and protein dietary in-
take, a fasting morning urine sample for the determination of
calcium and creatinine is obtained from the patient. If urine cal-
cium excretion normalizes, with the ratio of urine calcium/crea-
tinine falling below the value of 0.11 mg/mg, the diagnosis of
Absorptive Hypercalciuria can be made. If urine calcium excre-
tion remains elevated in spite of dietary calcium deprivation,
the diagnosis of Fasting Hypercalciuria is reasonable. On the
basis of serum calcium and PTH values, this form can be fur-
ther classified as Undetermined Fasting Hypercalciuria or Re-
nal Hypercalciuria. 
PH and bone disease
The size of the problem
Since the Seventies, the hypothesis that continuous elevation
in urine calcium excretion could be associated with some de-
gree of bone loss has been more clearly defined. Due to the
fact that idiopathic hypercalciuria is one of the most common
phenotypes in patients with kidney stones, the large majority
of the studies undertaken to assess bone status in hypercal-
ciuric patients were conducted in patient with calcium
nephrolithiasis. On the whole, these studies demonstrated
that while bone density is substantially normal or only slightly
reduced in patients with calcium nephrolithiasis without hy-
percalciuria, significant bone loss is present in patients with
kidney stones and primary hypercalciuria (Tab. II). Bone loss
seems to mainly involve those skeletal sites where trabecular
bone is more represented, such as vertebral bodies (22-35).
However, a reduction in femoral density was reported by sev-
eral authors (28, 29, 31-36). There are no data on the number
of hypercalciuric patients who suffer from an established os-
teoporotic bone disease as defined by WHO classification
(37). Yet, the rate of demineralization is generally substantial,
ranging from 10 to 15% as compared to age- and sex-
matched normal subjects (24, 26-28, 31, 33). Some authors
reported even more significant decreases in bone density
(25). The importance of these results from a clinical point of
view is further strengthened by the relatively young age (ap-
proximately 50 years) of these patients and by the large pro-
portion of males in the studied populations. 
There are no data on the role of hypercalciuria as a risk factor
for fractures. However, an increased fracture risk was reported
in patients with renal calculi (38, 39). There is no direct evi-
dence in these studies that hypercalciuria per se is responsible
for the increased fracture risk in these patients. However,
among patients with kidney stones bone loss is a predominant,
if not exclusive, characteristic of hypercalciuric subjects. Con-
sequently, it can be speculated that hypercalciuria can be at
least one of the factors explaining the increased proportion of
fragility fractures seen in these patients. 
Besides the wide overlap between the pathophysiology of ab-
sorptive and fasting hypercalciuria, the differences in bone in-
volvement in patients with these two forms of hypercalciuria
are still matters of debate. While most authors specifically ob-
served a significant proportion of bone loss in patients with
fasting hypercalciuria but not in those with the absorptive form
(24-26, 31, 33), others reported a decrease in bone density ir-
respective of the type of primary hypercalciuria (27, 29, 30),
Figure 1 - Flow-chart for the classification of Primary Hypercalciuria.
After one week of low calcium (≤ 400 mg/day), normosodic (100-150
mmol/day) and normoproteic (1-1.2 g/kg BW) diet, a fasting morning urine
sample (h. 7.00-9.00 a.m.) should be obtained for the determination of cal-
cium and creatinine.
Normal serum calcium and
Undetermined
Fasting
Hypercalciuria
Renal
Hypercalciuria
Elevated PTH and
normal/low
serum Ca
Normal PTH
and serum
Ca
Fasting Hypercalciuria Absorptive Hypercalciuria
> 0.11 mg/mg < 0.11 mg/mg
Urine Ca/Cr
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that is, even in patients classified as having Absorptive Hyper-
calciuria (27-29). Theoretically, the latter finding could appear
rather surprising, if one considers that patients with Absorptive
Hypercalciuria should be protected from bone loss by the same
mechanism generating hypercalciuria – that is, increased in-
testinal calcium absorption – with a consequent positive calci-
um balance. However, as to this point, several aspects have to
be considered. For one thing, some of the studies focusing on
this specific issue were unfortunately carried out population
samples that were on too small, which made it difficult to prop-
erly compare the consequences on bone of the two forms of
hypercalciuria (29). Secondly, a negative effect on bone of a
low calcium diet, inappropriately prescribed by the patients
themselves or by the physician in order to reduce intestinal cal-
cium absorption, may in turn induce a decrease in bone density
even in patients with Absorptive Hypercalciuria. This was ap-
parently the case of the study by Pietschmann et al. (27), who
found that their patients with absorptive hypercalciuria had low
bone density, although its prevalence was of limited impor-
tance as compared to patients with fasting hypercalciuria. Addi-
tionally, they speculated that low bone density might also be a
consequence of the excessive stimulation of bone resorption
resulting from high consumption of dietary protein, increased
serum levels of 1,25-(OH)2 vitamin D, or sensitivity to this hor-
mone in these patients.
New and more intriguing hypotheses are currently being con-
templated to solve this issue. One possible explanation is the
fact that the absorptive and fasting types of hypercalciuria may
not be two truly different forms of defect, but rather a unique
disorder, possibly consisting in a systemic alteration of calcium
transport that may present a prevalence of intestinal calcium
absorption or bone loss. The major support to this view is a re-
cent study in which it was found that hypercalciuric patients
with the largest proportion of bone loss also present the high-
est levels of intestinal calcium absorption (35). 
Bone disease type
One of the most puzzling aspects of bone disease in patients
with PH is its nature. As a matter of fact, bone histomorphome-
tric studies are rare in this setting and have not yielded homo-
geneous results. Bone resorption activity seems to be either in-
creased (40-42) or normal (43), while the most common histo-
logical alteration is a reduction in bone formation function, as
observed by most authors (40-45). These results tend to be in
contrast with those reported for bone turnover markers. Most
authors observed increased levels of both bone formation and
resorption markers in hypercalciuric patients (24-26, 31, 33,
46). Additional uncertainness may arise from the observation of
a moderate to severe mineralization defect, associated with a
prolonged mineralization lag (40, 42, 43, 45). Increased osteoid
thickness was also reported by Thomas and coworkers (44).
Because of the differences in the study populations (type of
PH, sex, age, dietetic conditions, and so on) these findings
cannot be univocally interpreted. However, taken as a whole,
these data seem to refer to a type of skeletal alteration ranging
from a moderately low-turnover osteoporosis to an osteoma-
lacic trait. 
Pathophysiology
Whatever the pathophysiological mechanism, the fact that
primary hypercalciuria and bone diseases are strictly linked
is well-established on the ground of several direct and indi-
rect observations. The rate of urine calcium excretion was
found to correlate with bone loss (29, 35, 47) and elevation
in bone turnover markers in hypercalciuric patients (25, 31,
33, 46). In addition, several retrospective and prospective
studies showed that thiazide use is associated with a reduc-
tion in fracture incidence (48-53) and an increase in bone
density (54-56). Although thiazides may act directly on bone
resorption (55, 56), the reduction in renal calcium excretion
remains the most important contributing factor to the im-
provement in bone density detected in thiazide-treated sub-
jects (54-56). 
To understand the relationships between PH and bone loss
and the pathogenetic factors shared by the two conditions is
even more difficult. For this review, we will briefly examine the
role of bone, kidney, and intestine in the pathogenesis of skele-
tal alterations of PH.
Table II - Bone mineral density (BMD) in patients with primary hypercalciuria.
Author (reference), year Measurement method Measurement site Result of BMD
Lawoyin et al. (22), 1979 SPA Radius N ↓
Fuss et al. (23), 1983 SPA Radius ↓
Pacifici et al. (24), 1990 QCT Spine ↓
Bataille et al. (25), 1991 QCT Spine ↓
Borghi et al. (26), 1991 DPA Spine ↓
Pietschmann et al. (27), 1992 DEXA, SPA Spine, radius ↓
Jaeger et al. (28), 1994 DEXA Spine, femur ↓
Weisinger et al. (29), 1996 DEXA Spine, femur ↓
Ghazali et al. (30), 1997 QCT Spine ↓
Giannini et al. (31), 1998 DEXA Spine, femur ↓
Misael da Silva et a.l (32), 2002 DEXA Spine, femur ↓
Tasca et al. (33), 2002 DEXA Spine, femur ↓
Asplin et al. (34), 2003 DEXA Spine, femur ↓
Vezzoli et al. (35), 2003 DEXA Spine, femur ↓
Caudarella et al. (36), 2003 DEXA, QUS Radius, finger ↓
DEXA: Dual Energy X-ray Absorptiometry; DPA: Dual Photon Absorptiometry; QCT: Quantitative Computed Tomography; QUS: Quantitative UltraSound; 
SPA: Single Photon Absorptiometry; N: normal; ↓: reduced.
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1. Bone
Since the revision of the types of PH proposed by Levy et al.
(20), the term “fasting hypercalciuria” has been used to identify
patients who cannot lower or normalize their urine calcium ex-
cretion appropriately after a restriction in dietary calcium con-
sumption. As low bone density was more frequently reported in
these patients, the presence of some conditions causing simul-
taneously hypercalciuria and bone demineralization was sug-
gested.
Pacifici et al. (24) firstly reported that some cytokines contribut-
ing to the mechanisms that regulate bone resorption may be in-
volved in the pathogenesis of bone in patients with PH. They
found that monocytes in patients with fasting hypercalciuria,
but not in those with the absorptive form, produced an exag-
gerated amount of interleukin-1 (IL-1), a well-known very po-
tent stimulator of bone resorption processes (57), which in turn
was correlated with a significant degree of bone demineraliza-
tion. The role of cytokines in this setting was then confirmed by
other reports. Weisinger and coworkers (29) found that the pro-
duction and mRNA expression of IL-1α from unstimulated pe-
ripheral blood mononuclear cells correlated with spinal bone
loss in patients with PH and nephrolithiasis. In addition, the
same cells produced an increased amount of IL-1α, interleukin-
6 (IL-6), and Tumoral Nechrosis Factor-α (TNF-α) as com-
pared to controls after stimulation with lipopolysaccharide
(LPS). Since all these cytokines are considered local mediators
of bone resorption (58), the authors concluded that bone loss
may largely depend upon these alterations in hypercalciuric pa-
tients with calcium stones. Similar results were obtained by
Ghazali et al. (30), who found that IL-1β, IL-6, TNF-α, and
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF)
from peripheral blood monocytes were involved in the patho-
genesis of bone loss in patients with PH. The consistency of all
these results undoubtedly strengthens the importance of cy-
tokines as pathogenetic factors of bone loss in PH (Tab. III).
However, it remains to be elucidated whether overproduction of
these cytokines from bone and bone marrow cells is also pre-
sent. Indeed, even if it is believed that altered cytokine secre-
tion from peripheral mononuclear cells may in some way reflect
a similar pattern in bone marrow (59), all these bone-reabsorb-
ing substances are mainly considered local regulating factors
of cell differentiation and function (58). In addition, no clear ex-
planations were given for such an alteration in cytokine secre-
tion in patients with PH and no differences in IL-1β gene poly-
morphism were found between patients with or without PH
(60). 
Other factors are thought to be involved in bone alteration in
PH. One of the most studied features is the effect of protein in-
take in these patients. Excessive protein intake, especially of
animal origin, was found to sharply increase urine calcium ex-
cretion and bone resorption and lead to bone loss (11). The
main responsible mechanism for these effects is the acid load
produced by proteins, especially by those rich in sulfur-contain-
ing amino acids (11). Accordingly, it was demonstrated that
sulfate excretion and some markers of protein intake, such as
urinary or serum urea, well correlate with bone turnover mark-
ers and density (25, 27, 28, 61). We also found that a moder-
ate protein restriction was accompanied by a proportional re-
duction in calcium excretion and bone turnover markers in pa-
tients with nephrolithiasis and PH (61). Since dietary protein
excess was repeatedly reported in hypercalciuric stone formers
(11, 61) and hypersensitivity to protein effects on bone was al-
so suggested, normalization of protein intake is highly recom-
mended in hypercalciuric patients. 
No consistent data currently support the substantial role of cal-
ciotropic hormones in the pathogenesis of bone loss in PH.
1,25-(OH)2 vitamin D was reported to be higher in PH patients
than in controls and it was observed that this hormone can in-
duce an increase in bone resorption (62). However, the eleva-
tion in 1,25-(OH)2 vitamin D levels was more frequently de-
scribed in patients with absorptive hypercalciuria, whose bone
density levels are generally normal or poorly diminished.
Bataille et al. (25) also found that 1,25-(OH)2 vitamin D levels
have a protective rather than a damaging effect on bone mass
in patients with PH and kidney stones. Apart from the very
small proportion of patients that can be classified as having re-
nal hypercalciuria (20), PTH levels are generally normal in PH
patients and are not thought to have a significant role in the
pathogenesis of bone loss in this setting. 
2. Intestine 
Although the classical distinction of PH in absorptive and fast-
ing hypercalciuria is still maintained, a wide overlap seems to
occur between the two forms. Besides, the intestinal function
plays a key role both in the pathogenesis of PH and in the de-
velopment or maintenance of bone disease. As mentioned
above, some studies also reported a decrease in bone density
in patients with absorptive hypercalciuria (27). On the other
hand, increased intestinal calcium absorption is frequently pre-
sent even in patients with fasting hypercalciuria (19). Vezzoli
and coworkers recently reconsidered the complex relationships
between intestine and bone in patients with PH in a very inter-
esting study (35). They assessed intestinal calcium absorption
in hypercalciuric patients through the stable strontium method.
They found that the greater the loss of bone mineral density,
the larger the increase in intestinal calcium absorption, the lat-
ter being the best predictor of bone mass in a multiple regres-
sion model (Fig. 2). Since PTH values were similar in hypercal-
ciuric and normocalciuric stone formers, they speculated that
this is not a compensatory phenomenon, but probably the
Table III - Cytokines levels from peripheral blood mononuclear cells in patients with PH and controls.
Author Population sample IL-1 IL-1α IL-1β IL-6 TNF-α GM-CSF 
Pacifici et al. (24) FH, AH, Controls 261±81a – – – – –
Weisinger et al. (29) IH, NC, Controls – 680±139b – 19±4c 2976±417b –
Ghazali et al. (30) IH, DH, Controls – – 40±21d 347±145e 236±136 52±27e
FH = Fasting Hypercalciuria; AH = Absorptive Hypercalciuria; IH = Idiopathic Hypercalciuria; NC = Normocalciuria; DH = Dietary Hypercalciuria; LPS =
Lipopolysaccharide
a FH P < 0.01 vs AH and Controls
b IH P < 0.01 vs NC and Controls (LPS-stimulated)
c IH P < 0.05 vs NC and Controls (LPS-stimulated)
d IH P < 0.01 vs DH
e IH P < 0.05 vs Controls.
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marker of disturbed cell calcium transport, involving both in-
testinal and bone tissues (35). This hypothesis would also be in
keeping with the view that absorptive and fasting hypercalciuria
may be different phenotypes and expressions of the same dis-
order (21). Although its nature is not fully understood, some ge-
netic influences might be possible (63). 
Whatever the explanation for the increased intestinal calcium
absorption in patients with PH, the importance of this obser-
vation is further strengthened by the fact that, in the absence
of proportional intestinal calcium hyperabsorption, the nega-
tive calcium balance observed in patients with fasting hyper-
calciuria should be much larger than it actually is, with a
tremendous impact in terms of bone loss and fracture risk.
Even if intestinal calcium absorption varies according to di-
etary calcium intake, food quality, intestinal function, serum
1,25-(OH)2 vitamin D, and so forth, approximately 4-5 mmol of
calcium are absorbed daily through the gut and the same
amount is eliminated with the urines (Fig. 3, ref. 63). In the
presence of hypercalciuria, calcium balance can be main-
tained only at the expenses of the skeletal tissue or through
an increase in intestinal calcium absorption, which can in turn
limit bone loss. The restriction in dietary calcium intake, which
many hypercalciuric patients tend to do by themselves or af-
ter medical prescription, is therefore a major risk factor for
bone loss in this setting. Indeed, it was clearly seen that a re-
duction in calcium intake is associated with negative calcium
balance and bone loss in hypercalciuric patients (28, 64, 65).
Some authors (64, 65) reported this negative effect after a
calcium-restricted diet of 2-8 years, while Jaeger et al. ob-
served a significant reduction in bone density in hypercalciuric
patients already after the first year of low calcium diet (9). In
addition, Curhan et al. (66) reported that dietary calcium re-
striction does not reduce the incidence of new kidney stones
but, in fact, it increases the risk of developing new sympto-
matic renal calculi, at least in males. This seems to occur be-
cause of the increase in intestinal oxalate absorption with a
secondary increase in urinary excretion in the absence of cal-
cium in the colon. All these observations suggest that hyper-
calciuric patients need to maintain an appropriate dietary cal-
cium intake.
Figure 2 - Multiple stepwise regression analysis showing that lumbar-spine
BMD z-score was negatively associated with enteral strontium absorption
(AUC, x axis) in hypercalciuric stone-forming women (reproduced with
permission by Vezzoli et al., ref. 35).
Figure 3 - Anatomic sites of calcium flux. The figure shows the major sites of calcium flux in the body with indication of the average amounts of daily calci-
um flux. Dietary (D) calcium (Ca) undergoes net absorption (a) through the intestine into the extracellular fluid (ECF). Daily bone resorption (Br) and forma-
tion (Bf) are equal. The filtered load (FL) of calcium is substantially reabsorbed (fr, fractional reabsorption) in the kidney, resulting in urine (U) calcium excre-
tion that is virtually identical to the amount absorbed in the intestine (reproduced with permission from Frick and Bushinsky, ref. 63).
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3. Kidney 
The presence of renal calcium leak is the basis for the so-
called renal hypercalciuria, which is characterized by increased
urine calcium, a tendency toward hypocalcemia, and a sec-
ondary increase in parathyroid hormone secretion that is con-
sidered the main cause of bone loss in these patients (64).
However, the large revision of the pathogenetic aspects of pa-
tients with PH led to the observation that less than 5% of hy-
percalciuric patients suffer from a renal form of PH (20). As a
consequence, the importance of renal calcium leak as a patho-
genetic factor for bone loss in these patients was completely
reconsidered. 
However, some other aspects seem to link the kidney to the
complex relationships occurring between hypercalciuria and
bone. Increased urinary phosphate excretion was found in hy-
percalciuric patients as compared to normal subjects, irrespec-
tive of the presence of a true form of absorptive hypercalciuria
with renal calcium leak (67). It was suggested that excessive
excretion of phosphate may be present in the majority of pa-
tients with PH, then concurring to the development of the hy-
percalciuric state in the whole population of PH patients. Simi-
lar findings were reported by Prié et al. (68) in hypercalciuric
stone formers. They observed that the distribution of renal
phosphate threshold normalized for glomerular filtration rate
(TmPi) was quite different between patients and controls, with
hypercalciuric patients showing a decreased value of TmPi in
approximately 20% of cases. No assessment of bone status
was made in the two papers. However, it could be hypothe-
sized that the alteration in phosphate metabolism seen in these
patients plays a role also in the pathogenesis of bone damage
in hypercalciuric patients. Hereditary hypophosphatemic rickets
with hypercalciuria (HHRH) is a paradigm of this pathophysiol-
ogy (69). This disease shares some clinical aspects with the
disorder seen in the Npt2 knockout mice, carrying the deletion
of the gene of kidney-specific Na-Pi cotransporter, in which a
delay in bone mineralization is seen 21 days after birth. These
bone alterations may resemble those observed in hypercalci-
uric patients in histomorphometric studies (40-45), in which an
alteration in the bone mineralization process was reported. Ac-
cordingly, a mutation of NPT2 gene was found in nephrolithia-
sic patients with decreased bone density by Prié and cowork-
ers (70). In conclusion, even if no clear evidence supports the
hypothesis that renal phosphate leak may be, at least in part,
responsible for bone disease in PH patients, this research field
appears as one of the most promising to better elucidate the
role of kidney in the pathogenesis of bone loss in PH.
Primary Hypercalciuria and Osteoporosis
Despite the evidence that Primary Hypercalciura is very fre-
quently associated with bone loss and the fact that 24-hour
urine collection for calcium assessment is recommended by
the large majority of the international guidelines on the diag-
nostic process for osteoporotic patients, no systematic attempt
has been made to ascertain the role of this defect in patients
with osteoporosis up to the last two years. Tannenbaum and
colleagues (71) first reported prevalence of Primary Hypercalci-
uria of about 10% in a large sample of otherwise healthy
women with osteoporosis. In 2002, Deutschmann et al. found
that idiopathic hypercalciura was present in about 10% of their
patients with apparent primary osteoporosis, with a frequency
of 7.7% in females and 20.7% in males (72). In the same year,
Peris et al. described prevalence of hypercalciuria of about
20% in premenopausal women with osteoporosis, but without
any signs or symptoms of associated diseases. (73). These
studies are very important because they clearly point out the
fact that a very large proportion of patients with otherwise pri-
mary osteoporosis may have an idiopathic form of hypercalci-
uria. However, no specific attempt was made by these authors
to correlate the presence of hypercalciuria with bone loss. We
retrospectively analyzed data of 241 otherwise healthy women
referred to our Unit because of osteoporosis and reported the
presence of Primary Hypercalciuria in 19% of the subjects.
When these patients were compared with osteoporotic subjects
without hypercalciuria, the only differences detected between
the two groups apart from urine calcium were urinary phos-
phate and renal tubular phosphate reabsorption (74). However,
the level of hypercalciuria was the most important predictor of
bone loss only in patients carrying this defect, with calciuria ac-
counting for more than 50% of the variance in spinal bone den-
sity. Noteworthy is that the levels of renal tubular reabsorption
of phosphate were strongly associated with the probable pres-
ence of hypercalciuria (OR 0,33, 95% C.I. 0,18-0,62). We inter-
preted these data as a further demonstration of the close rela-
tionship between hypercalciuria and bone loss, even in patients
with an osteoporotic phenotype rather than with kidney stones.
This further stresses the need for a proper evaluation of calci-
um metabolism in osteoporotic patients and for a thorough
analysis of the complex pathophysiological relationship be-
tween bone disease and hypercalciuria so as to transfer these
new findings into a more appropriate and specific therapeutic
option.
On the basis of the above considerations, the pathogenesis of
the bone disease affecting subjects with both osteoporosis and
hypercalciuria may not differ from that of patients with kidney
stones, reduced bone mass, and primary hypercalciuria. How-
ever, some other mechanisms may contribute to an increase in
urine calcium in postmenopausal women with osteoporosis.
Heshmati et al. (75) found that postmenopausal women with
osteoporosis had a defect in renal calcium conservation as
compared to subjects with normal bone density matched for
sex and menopausal status. This effect was not dependent up-
on PTH. Since estrogens can exert their actions even on renal
tubules, the authors concluded that estrogen responsiveness
may be altered in postmenopausal osteoporotic women, then
inducing both an increased skeletal calcium outflow and renal
calcium losses. Even if this mechanism is likely to occur in
women with osteoporosis and primary hypercalciuria too, there
is no direct evidence that can confirm this intriguing hypothesis
in this subset of patients.
Conclusions
Primary Hypercalciuria is a very common finding in patients
with kidney stones and otherwise primary osteoporosis. It is
now clear that the association between bone loss and PH does
not follow a chance pattern, but it is characterized by a very
close relationship. However, the mechanisms involved in the
pathogenesis of bone damage in hypercalciuric patients still re-
main only partially understood. On the other hand, most of the
organs and tissues normally involved in the control of calcium
and phosphate metabolism seem to take an active part in the
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Table IV - Prevalence of PH in otherwise healthy osteoporotic pa-
tients.
Author Year Prevalence of PH
Tannenbaum et al. (71) 2002 09.8%
Deutschmann et al. (72) 2002 10.3%
Peris et al. (73) 2002 021%
Giannini et al. (74) 2003 019%
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pathogenesis of the skeletal alterations in patients with PH.
The skeletal tissue per se, kidney, and intestine seem to be re-
sponsible for the appearance, maintainance, and clinical
course of bone loss in hypercalciuric patients, and to operate
together in a pattern of multi-tissue metabolic disorder. The
adoption and sharing of common laboratory criteria worldwide
to promptly detect the presence of PH will improve the knowl-
edge in this field, which will allow a more successful clinical
and therapeutic approach in this very complex and intriguing
matter. 
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